MMP11 and leiomyoma: MMP11 seems to be the most promising target for the development of target therapy of leiomyoma, since it is not expressed in any of the normal tissues of the body; however, a sustainable therapeutic effect of leiomyomata is expected only if the MMP11 inhibitor is combined with blockers of some other targets.